Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,693 matching trials from the live ClinicalTrials.gov search.
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers

NCT07531316
Conditions
Healthy Controls
Interventions
Placebo pills for 14-day intervention, VVZ-2471 for 14-day intervention
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
4 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Conditions
Diastolic Heart Failure
Interventions
Sitexsentin sodium, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 39 more
Conditions
HIV Associated Neurocognitive Disorder
Interventions
Fluconazole, Paroxetine, Paroxetine and Fluconazole, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Arteriovenous Malformations (Extracranial)
Interventions
Cobimetinib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
2 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Metastatic Breast Cancer
Interventions
PMD-026, fulvestrant
Drug
Lead sponsor
Phoenix Molecular Designs
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Gilbert, Arizona • Duarte, California • Irvine, California + 7 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Desert Harvest Aloe Vera Capsules, Placebo Capsules
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 2 Interventional Results available

Daily Liraglutide for Nicotine Dependence

NCT03712098
Conditions
Smoking Cessation, Weight, Body
Interventions
Liraglutide, Placebo, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
Rebecca Ashare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Myelodysplastic Syndrome, Leukemia
Interventions
Cord Blood Infusion, Busulfan, Fludarabine, Rituximab, ATG, Cyclophosphamide, Clofarabine, Total Body Irradiation (TBI), Melphalan, Tacrolimus, Mycophenolate Mofetil, G-CSF
Procedure · Drug · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Interventions
rhIGF-1 (mecasermin, Tercica, Inc.)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years to 12 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Brisbane, California
Conditions
Glioblastoma
Interventions
BBI608, Temozolomide
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Results available

Diurnal Variation of Plasminogen Activator Inhibitor-1

NCT00515021
Conditions
Metabolic Syndrome X
Interventions
Eplerenone (Morning), Eplerenone (Night-time)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Body Dysmorphic Disorder
Interventions
Levetiracetam
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

NCT01953432
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
Interventions
DCR-MYC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 5 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Gainesville, Florida • Pensacola, Florida • Atlanta, Georgia + 2 more
Conditions
Bipolar Disorder
Interventions
Placebo, Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
66
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 51 more
Conditions
SARS-CoV Infection, Covid19
Interventions
Nitazoxanide, Placebo Nitazoxanide, Ribavirin, Placebo Ribavirin, Hydroxychloroquine, Placebo Hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Richter Syndrome
Interventions
Venetoclax, DA-EPOCH-R, R-CHOP
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio • Houston, Texas
Conditions
Brain Metastases, HR+ Metastatic Breast Cancer
Interventions
Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Completed Not applicable Interventional Results available

Adjusting Insulin Delivery to Activity

NCT02299479
Conditions
Diabetes, Nocturnal Hypoglycemia
Interventions
Dexcom G4 Platinum CGM, Activity monitor
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Transplant; Failure, Kidney
Interventions
Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids
Drug
Lead sponsor
Gaetano Ciancio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Conditions
Multiple Myeloma, Post Stem Cell Transplant
Interventions
Talquetamab, Talquetamab and Lenalidomide
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Palo Alto, California